Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Selective TYK2 Inhibitor (Allosteric — Regulatory Domain Binding)

Deucravacitinib (TYK2 Inhibitor — Psoriatic Arthritis/Psoriasis)

Brand names: Sotyktu

Deucravacitinib is an oral selective TYK2 inhibitor used in rheumatology and dermatology for moderate-to-severe plaque psoriasis and psoriatic arthritis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively binds the regulatory domain of tyrosine kinase 2 (TYK2), allosterically inhibiting signalling of interleukin-23, interleukin-12 and type-I interferons that drive psoriatic inflammation.

Prescribing in practice

  • As an immunomodulator it increases infection risk — screen for and treat latent tuberculosis and other infections before starting and avoid live vaccines.
  • Assess hepatic function and triglycerides, and avoid use in clinically significant active infection.
  • Prescribe under specialist supervision in line with the SPC and current prescribing references.

Monitoring

Monitor for signs of infection, and check liver function and lipids as clinically indicated during treatment.

Counselling the patient

  • Report fever, persistent cough or other signs of infection.
  • Ensure vaccinations are up to date before starting and avoid live vaccines.
  • Take regularly as prescribed and attend reviews.

Evidence & guidelines

Efficacy in moderate-to-severe plaque psoriasis is supported by phase 3 randomised controlled trials.

Reference: Armstrong et al. NEJM 2023 (POETYK PSO-1/PSO-2); MHRA Approval Sotyktu 2023; NICE Appraisal pending; Phase 3 POETYK PsA trial (ongoing); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways